Baron International Growth Fund increased in the third quarter of 2024, modestly outperforming its benchmark, the MSCI ACWI ...

Mangoceuticals (NASDAQ:MGRX), which operates the men’s health platform MangoRx, said it strongly refutes any and all claims ...

The Wegovy makers’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...

For the first time in a decade, the American Heart Association and American Stroke Association issued new recommendations for ...

For the first time in a decade, the American Heart Association and American Stroke Association issued new recommendations for preventing strokes.

Novo Nordisk’s oral semaglutide lowered the risk of certain heart events in a late-phase study in people with type 2 diabetes ...

Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...

Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the ...

Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is ...

Novo Nordisk faces growth deceleration but shows promise. Learn more about NVO stock and why its risk/reward profile may ...

The pill version of Novo Nordisk’s (NVO) blockbuster drug Ozempic was found to cut the risk of heart attacks, strokes, and ...